Risks and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Oct. 24, 2024	Mar. 31, 2024	Apr. 30, 2023	Aug. 31, 2022	Dec. 31, 2024	Dec. 31, 2023
Unusual Risk or Uncertainty [Line Items]
Accumulated deficit					$ 358,730	$ 320,889
Proceeds from the sale of product line					$ 5,440
Underwritten public offering
Unusual Risk or Uncertainty [Line Items]
Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)	14,670,000		5,219,190	4,600,000
Offering price (in dollar per share)	$ 2.25		$ 9.5	$ 8
Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses	$ 42,900		$ 46,300	$ 34,400
Warrant | Underwritten public offering
Unusual Risk or Uncertainty [Line Items]
Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)	5,800,000
Offering price (in dollar per share)	$ 2.2499
Exercise Price	$ 0.0001
MiMedx Group, Inc.
Unusual Risk or Uncertainty [Line Items]
Proceeds from the sale of product line		$ 5,000
Period of net sales considered for calculating additional future payment receivable		2 years
MiMedx Group, Inc. | Maximum
Unusual Risk or Uncertainty [Line Items]
Revenue sharing payments		$ 7,000
MiMedx Group, Inc. | Minimum
Unusual Risk or Uncertainty [Line Items]
Revenue sharing payments		$ 3,000